In late May, shares of Relypsa Inc RLYP 0.4% soared when the FDA rejected AstraZeneca plc (ADR) AZN 0.46%’s hyperkalemia drug ZS-9. The market is betting that the rejection will be good news for Relypsa’s Veltassa, which also treats hyperkalemia.

Slingshot Insights recently held an expert call related to the impact the FDA ruling will have on Relypsa. The expert was the chief of cardiology and co-director of the Heart Institute at Stony Brook University.

The expert explained how there are two main groups of hyperkalemia diagnoses: acute and chronic. According to the expert, there was significant enthusiasm for ZS-9 to treat the acute population. However, he doesn’t believe Veltassa will be widely used to treat patients in this population. Instead, he believes the largest end-market for Veltassa will be in treatment of chronic kidney disease.

“It’s…

Click here to continue reading

Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!